MX2016004834A - PROCESS FOR THE PREPARATION OF A PHOSPHODIESTERASE INHIBITOR (PDE4). - Google Patents
PROCESS FOR THE PREPARATION OF A PHOSPHODIESTERASE INHIBITOR (PDE4).Info
- Publication number
- MX2016004834A MX2016004834A MX2016004834A MX2016004834A MX2016004834A MX 2016004834 A MX2016004834 A MX 2016004834A MX 2016004834 A MX2016004834 A MX 2016004834A MX 2016004834 A MX2016004834 A MX 2016004834A MX 2016004834 A MX2016004834 A MX 2016004834A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- pde4
- phosphodiesterase inhibitor
- compound
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 title 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 2
- 239000000969 carrier Substances 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Proceso para la preparación de compuestos que poseen actividad inhibitoria de fosfodiesterasa (PDE4) de fórmula (I). La invención también se relaciona con el proceso para el aislamiento por cristalización del compuesto (I) y su uso para la preparación de composiciones farmacéuticas para inhalación en combinación con transportadores o vehículos adecuados. La presente invención también se relaciona con solvatos y formas cristalinas de un compuesto de fórmula (I). El producto sintetizado es adecuado para el uso en aplicaciones farmacéuticas por ejemplo en el tratamiento de enfermedades respiratorias.Process for the preparation of compounds that possess phosphodiesterase (PDE4) inhibitory activity of formula (I). The invention also relates to the process for crystallization isolation of compound (I) and its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystalline forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for example in the treatment of respiratory diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13189784 | 2013-10-22 | ||
| PCT/EP2014/072334 WO2015059050A1 (en) | 2013-10-22 | 2014-10-17 | Process for the preparation of a pde4 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016004834A true MX2016004834A (en) | 2016-07-19 |
| MX370104B MX370104B (en) | 2019-12-02 |
Family
ID=49385193
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014408A MX389002B (en) | 2013-10-22 | 2014-10-17 | PROCESS FOR THE PREPARATION OF A PHOSPHODIESTERASE (PDE4) INHIBITOR. |
| MX2016004834A MX370104B (en) | 2013-10-22 | 2014-10-17 | PROCESS FOR THE PREPARATION OF A PHOSPHODIESTERASE INHIBITOR (PDE4). |
| MX2022000030A MX2022000030A (en) | 2013-10-22 | 2016-04-14 | PROCESS FOR THE PREPARATION OF A PHOSPHODIESTERASE (PDE4) INHIBITOR. |
| MX2022000036A MX2022000036A (en) | 2013-10-22 | 2016-04-14 | Process for the preparation of a pde4 inhibitor. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014408A MX389002B (en) | 2013-10-22 | 2014-10-17 | PROCESS FOR THE PREPARATION OF A PHOSPHODIESTERASE (PDE4) INHIBITOR. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000030A MX2022000030A (en) | 2013-10-22 | 2016-04-14 | PROCESS FOR THE PREPARATION OF A PHOSPHODIESTERASE (PDE4) INHIBITOR. |
| MX2022000036A MX2022000036A (en) | 2013-10-22 | 2016-04-14 | Process for the preparation of a pde4 inhibitor. |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US9434691B2 (en) |
| EP (5) | EP3293176B1 (en) |
| JP (5) | JP6458957B2 (en) |
| KR (3) | KR102240865B1 (en) |
| CN (5) | CN105658629B (en) |
| AR (4) | AR098128A1 (en) |
| AU (1) | AU2014339136C1 (en) |
| BR (1) | BR112016008161B1 (en) |
| CA (3) | CA2928242C (en) |
| CY (1) | CY1123811T1 (en) |
| DK (3) | DK3293176T3 (en) |
| ES (3) | ES2759514T3 (en) |
| FI (1) | FI3587400T3 (en) |
| HR (3) | HRP20192152T1 (en) |
| HU (3) | HUE053112T2 (en) |
| IL (4) | IL285528B2 (en) |
| LT (2) | LT3293176T (en) |
| MX (4) | MX389002B (en) |
| MY (1) | MY182559A (en) |
| PH (3) | PH12021550257A1 (en) |
| PL (3) | PL3293176T3 (en) |
| PT (3) | PT3060551T (en) |
| RS (2) | RS65452B1 (en) |
| RU (1) | RU2682660C9 (en) |
| SG (4) | SG10201912852YA (en) |
| SI (3) | SI3060551T1 (en) |
| TW (3) | TWI651305B (en) |
| UA (2) | UA121853C2 (en) |
| WO (1) | WO2015059050A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX346424B (en) | 2010-08-03 | 2017-03-21 | Chiesi Farm Spa | Dry powder formulation comprising a phosphodiesterase inhibitor. |
| MX389002B (en) * | 2013-10-22 | 2025-03-20 | Chiesi Farm Spa | PROCESS FOR THE PREPARATION OF A PHOSPHODIESTERASE (PDE4) INHIBITOR. |
| EP3487501A1 (en) * | 2016-07-20 | 2019-05-29 | Allergan, Inc. | Methods, compositions, and compounds for treatment of dermatological and ocular conditions |
| JP7361584B2 (en) * | 2018-12-19 | 2023-10-16 | 高砂香料工業株式会社 | Method for producing amines by reduction of amides |
| JP6780763B2 (en) | 2018-12-25 | 2020-11-04 | トヨタ自動車株式会社 | Internal combustion engine control device |
| US11149615B2 (en) | 2018-12-25 | 2021-10-19 | Toyota Jidosha Kabushiki Kaisha | Control device for internal combustion engine |
| CN111808029A (en) * | 2020-08-31 | 2020-10-23 | 兰晟生物医药(苏州)有限公司 | Preparation method of PDE4 inhibitor clobiplane |
| CN118475343A (en) | 2021-12-21 | 2024-08-09 | 凯西制药公司 | Dry powder formulation filled in an inhaler with improved moisture resistance |
| US20250288568A1 (en) | 2022-04-27 | 2025-09-18 | Chiesi Farmaceutici S.P.A. | New crystal form of a pde4 inhibitor |
| CN115304542B (en) * | 2022-07-18 | 2024-02-02 | 湖南华纳大药厂手性药物有限公司 | A kind of synthesis technology of 3-hydroxypyridine |
| WO2024027901A1 (en) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Predictive biomarker of clinical response to a pde4 inhibitor |
| CN119923251A (en) | 2022-09-22 | 2025-05-02 | 奇斯药制品公司 | Capsule inhaler for administering phosphodiesterase-4 inhibitors |
| IL319639A (en) | 2022-09-22 | 2025-05-01 | Chiesi Farm Spa | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
| CA3268243A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farm Spa | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
| KR20250079386A (en) | 2023-11-27 | 2025-06-04 | 국립한국해양대학교산학협력단 | Apparatus and method for estimating unconfined compressive strength using multiple learning models based on images |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5935978A (en) * | 1991-01-28 | 1999-08-10 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
| AU2001239442A1 (en) * | 2000-03-30 | 2001-10-15 | Chirotech Technology Limited | Ruthenium-diphosphine complexes and their use as catalysts |
| WO2005026095A1 (en) * | 2003-09-12 | 2005-03-24 | Ranbaxy Laboratories Limited | Process for the preparation of roflumilast |
| EP1740593B1 (en) | 2004-04-19 | 2016-04-06 | KRKA, tovarna zdravil, d.d., Novo mesto | Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i |
| PT1749001E (en) * | 2004-04-29 | 2010-05-31 | Aventis Pharma Inc | 3-piperidinylisochroman-5-ols as dopamine agonists |
| KR20070079278A (en) | 2006-02-01 | 2007-08-06 | 삼성전자주식회사 | Apparatus and method for reducing channel switching time of receiver in digital multimedia system using receiver limitation system |
| ATE496029T1 (en) * | 2006-07-14 | 2011-02-15 | Chiesi Farma Spa | DERIVATIVES OF 1-PHENYL-2-PYRIDINYLALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS |
| HRP20110464T1 (en) * | 2006-12-22 | 2011-07-31 | Leo Pharma A/S | SUBSTITUTED ACETOPHENONES USED AS PDE4 INHIBITORS |
| EP2022783A1 (en) * | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| US20100015430A1 (en) | 2008-07-16 | 2010-01-21 | Outlast Technologies, Inc. | Heat Regulating Article With Moisture Enhanced Temperature Control |
| EP2216327A1 (en) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| ES2528957T3 (en) | 2010-06-14 | 2015-02-13 | Chiesi Farmaceutici S.P.A. | Crystalline form of glycopyrronium chloride |
| MX346424B (en) * | 2010-08-03 | 2017-03-21 | Chiesi Farm Spa | Dry powder formulation comprising a phosphodiesterase inhibitor. |
| EP2600829B1 (en) * | 2010-08-03 | 2017-06-14 | Chiesi Farmaceutici S.p.A. | Pharmaceutical formulation comprising a phosphodiesterase inhibitor |
| NZ610151A (en) | 2010-11-23 | 2015-06-26 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
| WO2012097479A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic inhibitors of anaphastic lymphoma kinase |
| CN103827088B (en) * | 2011-09-26 | 2017-10-13 | 奇斯药制品公司 | It is used as the derivative of the pyridyl alkyl alcohol of 1 phenyl 2 of phosphodiesterase inhibitors |
| WO2013087749A1 (en) | 2011-12-16 | 2013-06-20 | Chiesi Farmaceutici S.P.A. | Potentiation induced by pde4 inhibitors in the treatment of leukemia |
| AR093796A1 (en) * | 2012-12-05 | 2015-06-24 | Chiesi Farm Spa | ALCOHOL DERIVATIVES 1-PHENYL-2-PIRIDINIL ALQUILICO AS INHIBITORS OF PHOSPHODIESTERASE |
| CN103304408B (en) * | 2013-06-05 | 2016-10-05 | 威海迪素制药有限公司 | The preparation of roflumilast intermediate 3-ring the third methoxyl group-4-difluoro-methoxy-benzoic acid |
| US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| MX389002B (en) * | 2013-10-22 | 2025-03-20 | Chiesi Farm Spa | PROCESS FOR THE PREPARATION OF A PHOSPHODIESTERASE (PDE4) INHIBITOR. |
| KR101591785B1 (en) | 2013-12-24 | 2016-02-04 | 주식회사 투게더 | Apparatus for inputting data, System and Method for Transmitting Data Using the same |
| WO2019129586A1 (en) * | 2017-12-28 | 2019-07-04 | Chiesi Farmaceutici S.P.A. | Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis |
| CN118475343A (en) * | 2021-12-21 | 2024-08-09 | 凯西制药公司 | Dry powder formulation filled in an inhaler with improved moisture resistance |
-
2014
- 2014-10-17 MX MX2019014408A patent/MX389002B/en unknown
- 2014-10-17 EP EP17192278.4A patent/EP3293176B1/en active Active
- 2014-10-17 SI SI201431364T patent/SI3060551T1/en unknown
- 2014-10-17 PL PL17192278T patent/PL3293176T3/en unknown
- 2014-10-17 RU RU2016115246A patent/RU2682660C9/en active
- 2014-10-17 HR HRP20192152TT patent/HRP20192152T1/en unknown
- 2014-10-17 FI FIEP19183016.5T patent/FI3587400T3/en active
- 2014-10-17 KR KR1020167010773A patent/KR102240865B1/en active Active
- 2014-10-17 WO PCT/EP2014/072334 patent/WO2015059050A1/en not_active Ceased
- 2014-10-17 JP JP2016519348A patent/JP6458957B2/en active Active
- 2014-10-17 HU HUE17192278A patent/HUE053112T2/en unknown
- 2014-10-17 IL IL285528A patent/IL285528B2/en unknown
- 2014-10-17 DK DK17192278.4T patent/DK3293176T3/en active
- 2014-10-17 PL PL19183016.5T patent/PL3587400T3/en unknown
- 2014-10-17 PH PH1/2021/550257A patent/PH12021550257A1/en unknown
- 2014-10-17 KR KR1020217004798A patent/KR102287596B1/en active Active
- 2014-10-17 BR BR112016008161-7A patent/BR112016008161B1/en active IP Right Grant
- 2014-10-17 IL IL285532A patent/IL285532B2/en unknown
- 2014-10-17 LT LTEP17192278.4T patent/LT3293176T/en unknown
- 2014-10-17 DK DK14795565T patent/DK3060551T3/en active
- 2014-10-17 US US14/516,976 patent/US9434691B2/en active Active
- 2014-10-17 PL PL14795565T patent/PL3060551T3/en unknown
- 2014-10-17 EP EP20207308.6A patent/EP3798209A1/en active Pending
- 2014-10-17 HR HRP20240783TT patent/HRP20240783T1/en unknown
- 2014-10-17 MX MX2016004834A patent/MX370104B/en active IP Right Grant
- 2014-10-17 PT PT147955652T patent/PT3060551T/en unknown
- 2014-10-17 SI SI201431775T patent/SI3293176T1/en unknown
- 2014-10-17 HU HUE19183016A patent/HUE067681T2/en unknown
- 2014-10-17 CA CA2928242A patent/CA2928242C/en active Active
- 2014-10-17 KR KR1020217004799A patent/KR102287598B1/en active Active
- 2014-10-17 UA UAA201604362A patent/UA121853C2/en unknown
- 2014-10-17 MY MYPI2016000681A patent/MY182559A/en unknown
- 2014-10-17 EP EP19183016.5A patent/EP3587400B1/en active Active
- 2014-10-17 CN CN201480058065.XA patent/CN105658629B/en active Active
- 2014-10-17 EP EP22169035.7A patent/EP4059921A1/en active Pending
- 2014-10-17 DK DK19183016.5T patent/DK3587400T3/en active
- 2014-10-17 SI SI201432068T patent/SI3587400T1/en unknown
- 2014-10-17 SG SG10201912852YA patent/SG10201912852YA/en unknown
- 2014-10-17 SG SG10202112587RA patent/SG10202112587RA/en unknown
- 2014-10-17 ES ES14795565T patent/ES2759514T3/en active Active
- 2014-10-17 SG SG10201903575UA patent/SG10201903575UA/en unknown
- 2014-10-17 CA CA3115570A patent/CA3115570C/en active Active
- 2014-10-17 SG SG11201603130TA patent/SG11201603130TA/en unknown
- 2014-10-17 AU AU2014339136A patent/AU2014339136C1/en active Active
- 2014-10-17 PH PH1/2020/500162A patent/PH12020500162B1/en unknown
- 2014-10-17 CN CN202510734070.8A patent/CN120607463A/en active Pending
- 2014-10-17 RS RS20240463A patent/RS65452B1/en unknown
- 2014-10-17 UA UAA201909177A patent/UA127453C2/en unknown
- 2014-10-17 HU HUE14795565A patent/HUE046637T2/en unknown
- 2014-10-17 ES ES17192278T patent/ES2857629T3/en active Active
- 2014-10-17 CN CN202210366235.7A patent/CN114621139B/en active Active
- 2014-10-17 PT PT171922784T patent/PT3293176T/en unknown
- 2014-10-17 RS RS20210247A patent/RS61558B1/en unknown
- 2014-10-17 CN CN201910622800.XA patent/CN110256338A/en active Pending
- 2014-10-17 CA CA3115587A patent/CA3115587A1/en active Pending
- 2014-10-17 EP EP14795565.2A patent/EP3060551B1/en active Active
- 2014-10-17 CN CN202510293709.3A patent/CN120136784A/en active Pending
- 2014-10-17 LT LTEP19183016.5T patent/LT3587400T/en unknown
- 2014-10-17 PT PT191830165T patent/PT3587400T/en unknown
- 2014-10-17 ES ES19183016T patent/ES2980505T3/en active Active
- 2014-10-20 TW TW103136112A patent/TWI651305B/en active
- 2014-10-20 AR ARP140103938A patent/AR098128A1/en active IP Right Grant
- 2014-10-20 TW TW107133858A patent/TWI685486B/en active
- 2014-10-20 TW TW109102549A patent/TWI720803B/en active
-
2016
- 2016-04-14 MX MX2022000030A patent/MX2022000030A/en unknown
- 2016-04-14 MX MX2022000036A patent/MX2022000036A/en unknown
- 2016-04-20 PH PH12016500737A patent/PH12016500737B1/en unknown
- 2016-04-20 IL IL245220A patent/IL245220A/en active IP Right Grant
- 2016-07-22 US US15/217,468 patent/US9890122B2/en active Active
-
2017
- 2017-06-11 IL IL252834A patent/IL252834B/en unknown
- 2017-11-03 US US15/802,737 patent/US10323003B2/en active Active
-
2018
- 2018-10-05 JP JP2018189627A patent/JP2019038813A/en active Pending
-
2019
- 2019-04-23 US US16/391,952 patent/US10759761B2/en active Active
-
2020
- 2020-02-17 AR ARP200100438A patent/AR118124A2/en active IP Right Grant
- 2020-07-21 US US16/934,527 patent/US11352327B2/en active Active
- 2020-10-14 JP JP2020173216A patent/JP7051970B2/en active Active
-
2021
- 2021-02-15 CY CY20211100122T patent/CY1123811T1/en unknown
- 2021-03-01 HR HRP20210336TT patent/HRP20210336T1/en unknown
- 2021-05-27 AR ARP210101431A patent/AR122183A2/en unknown
- 2021-05-27 AR ARP210101430A patent/AR122182A2/en unknown
-
2022
- 2022-02-22 JP JP2022025300A patent/JP7534346B2/en active Active
- 2022-02-22 JP JP2022025240A patent/JP7345581B2/en active Active
- 2022-05-06 US US17/738,630 patent/US11981639B2/en active Active
-
2024
- 2024-01-02 US US18/401,832 patent/US20240166605A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019014408A (en) | Process for the preparation of a pde4 inhibitor. | |
| EA201792370A1 (en) | Pyrazolo- and triazo-pyrimidine compounds with antiviral activity in relation to RSV | |
| UY36112A (en) | IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE TO TREAT CANCER | |
| CL2017002650A1 (en) | Novel compounds | |
| CU20160065A7 (en) | COMPOUNDS OF (PIRROLO [1,2-f] [1,2,4] TRIAZINES, METHODS AND PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFECTIONS BY RESPIRATORY SYNTHETIC VIRUSES | |
| CU20190101A7 (en) | SUBSTITUTED DIAZABICYCLIC IMIDAZOPYRIMIDINES | |
| EA201791274A1 (en) | PYRAZOLO [1,5-a] PYRIDIDIN DERIVATIVES SUBSTITUTED BY PYRAMIDINE WITH INHIBITING ACTIVITY AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV) REPLICATION | |
| BR112014008045A2 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases | |
| BR112015009649A2 (en) | triazole compound | |
| DOP2016000308A (en) | COMPOUNDS OF 1, 3, 4-TIADIAZOL AND USE OF THE SAME FOR THE TREATMENT OF CANCER | |
| MX2015010003A (en) | C-19 modified triterpenoids with hiv maturation inhibitory activity. | |
| UY36875A (en) | BROMODOMINIUM INHIBITING COMPOSITIONS FOR THE TREATMENT OF VARIOUS DISEASES | |
| BR112017003242A2 (en) | compound, methods for treating virus infection and for the manufacture of a medicament, pharmaceutical composition, and use of a compound. | |
| PH12016502130A1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| CR20170513A (en) | USEFUL PIRAZOL DERIVATIVES AS INHIBITORS OF 5-LI-POXIGENASA ACTIVATING PROTEIN (FLAP). | |
| NI201500176A (en) | PRODROG DERIVATIVES OF SUBSTITUTED TRIAZOLPYRIDINES | |
| CR20170426A (en) | BACE INHIBITORS 1 | |
| BR112015030589A8 (en) | polymorphic forms of icotinib phosphate, pharmaceutical composition comprising said forms and uses thereof | |
| AU2014298561A8 (en) | Substituted pyridine-piperazinyl analogues as RSV antiviral compounds | |
| HK40009496A (en) | Antiviral compositions for the treatment of infections linked to coronaviruses | |
| UY33584A (en) | NEW BENZAMIDA COMPOUNDS OF LRRK2 INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |